We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CMXC Announces Results of Preliminary Analysis of Metabolomic Assays

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CMXC Announces Results of Preliminary Analysis of Metabolomic Assays"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cell MedX Corp. has announced that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.

The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Its main objective was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending.

Analysis of this early data set indicates substantial changes in at least two key pathways that would correlate with improvements in glucose and lipid metabolism. These findings will inform further experimentation, including the Phase 1B clinical trial, which begins recruiting in March 2015.

The analysis of the samples was conducted by The Metabolomics Innovation Centre at the University of Alberta (“TMIC”), whose analytic and informatics toolsets and translational “omics” expertise allows for cost-effective and more accurate results of assays.